An experimental breast cancer pill has stabilized or shrank tumors in nearly half of women who took it for eight weeks.

The oral drug, called lapatinib and made by GlaxoSmithKline, was tested in an early clinical trial by Kimberly Blackwell and colleagues from Duke University in Durham, North Carolina.

The researchers found that 46% of women with breast cancer who took the drug for two months saw benefit.

More here.